Joerg Ahlgrimm is the President and Chief Operating Officer at The Discovery Labs. He is an Operations and Supply Chain Management Executive who has served in multi-billion dollar companies operating in biotech, vaccines, pharmaceutical and medical device markets. He is the former Head of Global Operations Pharma and Biotech at Lonza AG where he was responsible for 37 sites on four continents. He focuses on strategy development and execution management, productivity improvement, organizational development, team building, and leadership in the implementation of “best practices.”

Alan Moore is Chief Strategy Officer at Discovery Labs. Alan oversees new client development and on-boarding. He has 40 years of experience in the Life Sciences contract services field and most recently served as Vice President and Head of Strategic Alliances at WuXi Advanced Therapies. He was responsible for developing and maintaining strategic manufacturing relationships for autologous, allogeneic and gene-mediated cell and gene therapies, strategic partnering in biologics services, and for alliance development in technology platforms and services supporting biologics and advanced therapies. Prior to that he served as Commercial Chief with primary responsibility for alignment of strategic partnering, business development efforts, and external collaborations. As VP Strategic Accounts and Cell Manufacturing he oversaw the capital investment and capacity expansion for advanced therapies manufacturing at the Philadelphia Navy Yard campus. Prior to WuXi, he served as Executive VP and Chief Business Officer at Althea Technologies following his service at Genzyme where he held a Senior Regulatory Coordinator and VP of Biopharm Development Services position and his business unit manufactured early personalized therapies in conjunction with the NCI for phase III clinical trials of B cell lymphoma and multiple myeloma. Alan spent 16 years at Bioreliance moving from the lab to quality, and eventual management of the Biotech Services Division, then served as Director Business Development.

Matthew Farabaugh is the Chief Financial Officer of The Discovery Labs. Matt has over 19 years of finance and business experience in clinical and basic research of immunology, oncology, cell and gene therapy, and infectious diseases. He was previously Finance Manager at WuXi Advanced Therapies where he was responsible for revenue and contract management of $100MM in US revenue for research, manufacturing, and testing portfolio related to cell and gene therapy products. Prior to this Matthew served as a member of the UPENN-Novartis Global Program Team under Dr. Carl June and was responsible for a $50MM annual clinical development plan focused on FDA approval of cutting-edge CAR T cell therapy Kymriah in pediatric patients with relapsed acute lymphoblastic leukemia. He has a BS in Microbiology from Duquesne University, an MS in Molecular Biotechnology from the University of Pennsylvania and finance training from the Wharton School of Business.

Dana Cipriano is VP of Testing and Analytical Services. Dana has a 20-year career in biotechnology with leadership roles focused on conceiving and designing processes and programs to drive sustainable growth and profitability. She was most recently Senior Director of Operations for WuXi AppTec where she directed operations for cell and gene therapy and biologics testing with a team of approximately 175 employees. She created the overall program strategy, drove tactical implementation plans and monitored key milestones to drive delivery of organizational objectives. She developed a fully integrated program for development of new corporate strategy centered on driving scalability in biologics testing services. Dana has a Masters in Microbiology from Thomas Jefferson University and a Bachelor’s in Biology from Rutgers University.

Mike McCormack is the VP of Quality and Compliance. Mike has over 17 years of experience in quality management within the biotechnology, cell and gene therapy and pharmaceutical industry with a proven track record of success maximizing performance, scaling quality commercial operations and streamlining quality systems, while maintaining the highest levels of compliance with global regulations over multi-site operations. Mike was most recently Vice President Quality Assurance and Regulatory Affairs at WuXi AppTec and was a QM Manager at Johnson Matthey Fine Chemicals. He has his MBA with an emphasis in Biotechnology and Health Industry from Penn State University and attended the University of the Sciences in Philadelphia where his field of study was Pharmacology and Toxicology.

Emily Moran is Senior Director of Vector Manufacturing. She is an experienced leader in Cell and Gene Therapy and Biologics Manufacturing with a focus on commercial readiness, industrialization, and manufacturing stabilization. She most recently was Head of Viral Vector Manufacturing at Lonza. She is experienced in Aseptic Processing, upstream and downstream processing, Viral Vector and Cell Therapy, Supply Chain and Demand Planning, Quality Auditing, CAPAs, and Lean Manufacturing Standards. She has a Bachelors in Biology from Ursinus College and an MBA from New York Institute of Technology.

Sybil Danby, Senior VP of Business Development and Strategy, joined The Discovery Labs with almost 15 years of industry experience across both technical and commercial roles. Most recently, Sybil was responsible for Business Development at Paragon Bioservices, which was acquired by Catalent Pharma Solutions in 2019 for $1.2 billion. In that role she interfaced with over 40 clients from top tier gene therapy companies, negotiated large strategic contracts, and more than doubled the business every year for three years straight. Prior to joining Paragon Sybil was part of the Single Use Technologies Business Unit at Pall, supporting upstream customers to adopt innovative single-use bioreactor technologies for the production of advanced therapies including AAV gene therapies, oncolytic viruses, and cell therapies. Sybil spent 9 years at GSK, working in both the Manufacturing and R&D organizations supporting the development, technology transfer, and manufacture of multiple clinical and commercial monoclonal antibody products. During her time at GSK Sybil developed extensive expertise in the area of bioreactor scaling and cell culture process development, contributing to the development and characterization of upstream processes for multiple products. Sybil obtained her B.A. in Biology from the University of Rochester and her M.S. in Biology from West Chester University of Pennsylvania.

Rich Heany is the President of MLP Ventures and has over 25 years of experience in real estate acquisitions, development, leasing and deal structuring. He has completed the acquisition and leasing of millions of square feet of real estate throughout the United States. Rich has a Degree in Civil Engineering from Drexel University and an MBA in Finance from LaSalle University.

Shailah Yazdani is Director of Lab Operations for Testing Centers of America. She has 11 years of continued success in healthcare and is a Lean Six Sigma Black Belt. She most recently was President and Region Head of Financial Operations at Parkway Clinical Laboratories. She has an MBA from Temple University Fox School of Management.

Oliver Mellet is the Vice President of Information Technology and Security of The Discovery Labs. Oliver has broad experience in delivering IT and IT Security solutions in the pharma and health care sectors at Merck and Penn Medicine in the support of cancer research, clinical trials, drug safety, GMP supply chain and manufacturing, and system security. He is known for delivering measurable results for complex problems in large scale corporate landscapes. He holds a BS in Mechanical Engineering and a Master’s degree in Management from the University of Pennsylvania (Wharton and SEAS)

Steve Gwynn is the Director of Enterprise Applications at The Discovery Labs. Steve has over 30 years experience in the Life Science industry as a leader in Information Technology, Supply Chain and Operations supporting both small and large molecule manufacturing domestically and internationally. Steve spent most of his career at Merck and came to Discovery Labs after several years as a Life Sciences consultant. As a consultant, Steve completed several projects at Bristol Myers Squibb and most recently Paragon Bioservices/Catalent Cell & Gene Therapy. Steve has extensive experience implementing and managing ERP systems for pharmaceutical/biologics operations and CDMOs. Steve has a Bachelor Degree in Chemical Engineering from the University of Delaware and an MBA with a focus in Operations from James Madison University.

Kevin is Project Director for the Operational Start-up of The Discovery Labs. He is an experienced project leader with nearly 15 years in the pharmaceutical industry and most recently served as a Global Tech Transfer Leader for Sanofi Pasteur. In this role, Kevin worked to identify and select external contract manufacturing and testing partners around the globe, and then implemented the technical and business processes between the two organizations. This expertise will prove to be particularly valuable in maximizing the customer experience. Kevin’s previous roles, within the industry, include work in Manufacturing Technology, Project Management, Manufacturing Excellence, Continuous Improvement, and Operations Management. He brings a strong project management and technical background as well as a solid understanding of supply chain, operational excellence, and strategic planning. He holds a Bachelor of Science in Kinesiology from Penn State University, a Master of Business Administration from the University of Scranton, and a PMP (Project Management Professional) certification.

Aldo Romano has over 20 years of Bioprocess, Cell and Gene Therapy experience in capital equipment and disposable process technologies. He was previously Business Development Manager at GE Healthcare Lifesciences where he was responsible for further developing their Enterprise Solutions business. Prior to this Aldo served at Advanced Scientific (now part of Thermo-Fisher) as a Healthcare Sales Manager in their OEM medical technology contract manufacturing unit. He began his career at Pall Corporation where he worked as a Director of Sales focused on the growth and adoption of single use technologies into the Biotech market. Aldo has a Bachelor’s degree in Biology from Binghamton University.
implementing overall marketing strategy, goals and campaigns. He is a recent graduate of The University of Delaware, he also played Division 1 Football at Wagner College.

Mr. O’Neill is the Director of Strategy and Special Projects where he oversees and manages marketing materials, client development and management, acquisitions strategy and rollout, and developing and implementing overall marketing strategy, goals and campaigns. He is a recent graduate of The University of Delaware, he also played Division 1 Football at Wagner College.

André Zeibari is Senior Director of Engineering and Automation at The Discovery Labs. Andre has nearly 25 years of experience in the life sciences industry with broad experience in designing, implementing, validating and maintaining operationally efficient and sustainable shop-floor automation and operational technologies, enterprise systems, and everything in between. He most recently developed and led the automation engineering organization at Paragon Bioservices responsible for automation systems in several gene therapy development and manufacturing sites.

Joe Corcoran has had an extensive and successful background in all aspects of the commercial real estate industry since 1983 when he started his career at the global brokerage real estate management company Cushman & Wakefield. After learning the trade at Cushman and successfully leasing the first office tower built in Conshohocken, Pennsylvania, Four Falls Corporate Center, Joe co-founded and formed Preferred Real Estate Advisors, the exclusive marketing arm of Preferred Real Estate Investments. He was a principal and a driving force in the successful growth of Preferred, and it’s development and leasing of over 4 million square feet which sold for over $350million in 2005, and was the largest suburban real estate portfolio sale in Philadelphia’s history at the time of the transaction. Joe later headed up The Flynn Company’s investment sales group, and became one of their top producers as a partner at the firm. Joe joined MLP Ventures and The Discovery labs as Executive Vice President and is overseeing the marketing and leasing of the campus. Joe holds an Economics Degree from Villanova University and served on the board on the Center for Real Estate at Villanova’s Business School.